Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» SAGE Therapeutics
SAGE Therapeutics
Sage continues downslide as Alzheimer’s study fails
BioPharma Dive
Tue, 10/8/24 - 10:00 pm
SAGE Therapeutics
Alzheimer's disease
clinical trials
SAGE-718
Sage scraps Alzheimer's program as dalzanemdor goes 0 for 2, leaving hopes resting on Huntington's
Fierce Biotech
Tue, 10/8/24 - 09:53 am
SAGE Therapeutics
Alzheimer's disease
dalzanemdor
clinical trials
Biogen cuts ties with Sage on failed tremor drug
First Word Pharma
Thu, 09/26/24 - 11:03 am
Biogen
SAGE Therapeutics
SAGE-324
essential tremor
Sage’s recent trial failure adds pressure to its two-drug Biogen collab
Pharma Voice
Mon, 07/29/24 - 10:29 am
SAGE Therapeutics
Biogen
clinical trials
SAGE-324
essential tremor
Zurzuvae
postpartum depression
Biogen, Sage Scrap Essential Tremor Study After Phase II Failure
BioSpace
Wed, 07/24/24 - 11:55 am
Biogen
SAGE Therapeutics
clinical trials
essential tremors
BIIB124
SAGE-324
Sage’s Dalzanemdor Shows Effect in Huntington’s Study, Analysts Say Results ‘Underwhelming’
BioSpace
Tue, 06/11/24 - 10:51 pm
SAGE Therapeutics
dalzanemdor
clinical trials
Huntington's disease
Sage Axes Parkinson’s Program for Dalzanemdor After Phase II Flop
BioSpace
Wed, 04/17/24 - 11:23 am
SAGE Therapeutics
clinical trials
Parkinson's Disease
dalzanemdor
A new $16,000 postpartum depression drug is here. How will insurers handle it?
Medical Marketing and Media
Wed, 03/13/24 - 11:11 am
zuranolone
postpartum depression
SAGE Therapeutics
Sage offers encouraging details on launch of new postpartum depression pill
BioPharma Dive
Wed, 02/14/24 - 06:42 pm
SAGE Therapeutics
postpartum depression
drug launches
Zurzuvae
In downsizing mode, Sage will move headquarters to a smaller space
Fierce Pharma
Thu, 01/25/24 - 11:17 am
SAGE Therapeutics
headquarters
Biogen
Biogen-Sage Therapeutics postpartum depression pill priced at $15,900
Reuters
Tue, 11/7/23 - 09:55 am
Biogen
SAGE Therapeutics
postpartum depression
drug pricing
Zurzuvae
Sage lays off 40%, shakes up C-suite to squeeze a profit out of partially rejected zuranolone
Fierce Biotech
Thu, 08/31/23 - 11:54 am
SAGE Therapeutics
layoffs
Biogen
major depressive disorcer
zuranolone
Brii Biosciences aims to come up big where Sage and Biogen fell short
Pharma Voice
Mon, 08/21/23 - 06:53 pm
Brii Biosciences
depression
SAGE Therapeutics
Biogen
BRII-296
postpartum depression
The Neuropsychiatric Pipeline: 10 Late-Stage Therapies to Watch
BioSpace
Mon, 08/14/23 - 11:23 am
depression
Biogen
SAGE Therapeutics
zuranolone
Intra-Cellular Therapies
lumateperone
Alto Neuroscience
ALTO-100
schizophrenia
Karuna Therapeutics
KarXT
Cerevel Therapeutics
emraclidine
Acadia Pharmaceuticals
pimavanserin
Axesome Therapeutics
AXS-05
Alzheimer's agitation
NRx
NRX-101
bipolar disorder
Biohaven
troriluzole
OCD
VistaGen
fasedienol
social anxiety
Biogen, Sage's postpartum depression approval overshadowed by larger rejection
Fierce Pharma
Mon, 08/7/23 - 12:01 pm
SAGE Therapeutics
Biogen
FDA
Zurzuvae
postpartum depression
major depressive disorder
FDA Approves Biogen, Sage’s Zurzuvae as First Pill for Postpartum Depression
BioSpace
Sun, 08/6/23 - 09:39 pm
Biogen
SAGE Therapeutics
FDA
Zurzuvae
postpartum depression
major depressive disorder
zuranolone
FDA Action Alert: Mesoblast, Sage/Biogen and Galera
BioSpace
Mon, 07/31/23 - 10:05 am
FDA
graft vs host disease
head and neck cancer
postpartum depression
major depressive disorder
Mesoblast
remestemcel-L
Biogen
SAGE Therapeutics
zuranolone
Galera Therapeutics
avasopasem manganese
Go or no go? Biogen and Astellas head towards key PDUFAs
EP Vantage
Sat, 07/29/23 - 10:45 pm
FDA
Astellas
Zimura
Biogen
SAGE Therapeutics
zuranolone
major depressive disorder
postpartum depression
geographic atrophy
Sage Stock Drops Despite Promising Phase III Depression Data
BioSpace
Thu, 07/27/23 - 11:30 am
SAGE Therapeutics
zuranolone
Biogen
depression
9 Highly Anticipated FDA Decisions in Second Half of 2023
BioSpace
Fri, 06/30/23 - 11:52 am
FDA
Eisai
Biogen
Leqembi
Alzheimer's disease
SAGE Therapeutics
zuranolone
postpartum depression
major depressive disorder
Roche
Tecentriq
non-small cell lung cancer
CRISPR Therapeutics
Bluebird Bio
lovo-cel
exa-cel
BrainStorm Cell Therapeutics
NurOwn
Pages
1
2
3
4
5
6
next ›
last »